UroGen Pharma (URGN) Tops Q1 EPS by 12c, Revenues Miss

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($1.17), $0.12 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $7.49 million versus the consensus estimate of $9.05 million.

“We are pleased with the progress we have made across our expanded pipeline and the momentum we’ve seen since we reported fourth quarter 2020 earnings in March. The number of patient enrollments, patient starts and doses shipped in April were each up more than 100% compared to January. We believe this signifies broader awareness of Jelmyto and increasing physician support,” said Liz Barrett, President and Chief Executive Officer of UroGen. “As we look to the remainder of 2021, with increased vaccination rates and eased COVID-19 restrictions across the United States, we feel confident that this momentum will continue as we advance our mission to bring novel solutions to patients with specialty cancers and urologic diseases.”

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• Innovaro (INV) Misses Q2 EPS by 9c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c